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Spinal neurons that contain
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extracellular signal-regulated kinases
in response to intradermal chloroquine
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Abstract
Background: Gastrin-releasing peptide (GRP) is thought to play a role in the itch evoked by intradermal injection of
chloroquine. Although some early studies suggested that GRP was expressed in pruriceptive primary afferents, it is now
thought that GRP in the spinal cord is derived mainly from a population of excitatory interneurons in lamina II, and it has been
suggested that these are involved in the itch pathway. To test this hypothesis, we used the transcription factor Fos and
phosphorylation of extracellular signal-regulated kinases (ERK) to look for evidence that interneurons expressing GRP were
activated following intradermal injection of chloroquine into the calf, in mice that express enhanced green fluorescent protein
(EGFP) in these cells.
Results: Injection of chloroquine resulted in numerous Fos- or phospho-ERK (pERK) positive cells in the somatotopically
appropriate part of the superficial dorsal horn. The proportion of all neurons in this region that showed Fos or pERK was
18% and 21%, respectively. However, among the GRP–EGFP, only 7% were Fos-positive and 3% were pERK-positive. As such,
GRP–EGFP cells were significantly less likely than other neurons to express Fos or to phosphorylate ERK.
Conclusions: Both expression of Fos and phosphorylation of ERK can be used to identify dorsal horn neurons activated by
chloroquine injection. However, these results do not support the hypothesis that interneurons expressing GRP are critical
components in the itch pathway.
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Background
Itch has been deﬁned as an unpleasant sensation that
causes a desire to scratch. Chronic itch (pruritus) can
result from several dermatological and systemic diseases
and represents a major unmet clinical need. Despite this,
we still know relatively little about the neuronal circuits
that are responsible for the sensation of itch.1–4 A major
distinction can be made between those forms of itch that
are relieved by antihistamines (histamine-dependent) and
those that are not (histamine-independent). Many sub-
stances (pruritogens) can evoke itch, when injected into
the skin, and these can operate through either histamine-
dependent or histamine-independent mechanisms.5–7
An early insight into the peripheral and spinal path-
ways responsible for itch came from the observation that
mice lacking the receptor for gastrin-releasing peptide
1Institute of Neuroscience and Psychology, College of Medical, Veterinary
and Life Sciences, University of Glasgow, Glasgow, UK
2School of Veterinary Medicine, College of Medical, Veterinary and Life
Sciences, University of Glasgow, Glasgow, UK
Corresponding author:
Andrew Todd, Institute of Neuroscience and Psychology, College of





! The Author(s) 2016
DOI: 10.1177/1744806916649602
mpx.sagepub.com
Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://
www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
(GRP) showed signiﬁcantly reduced responses to certain
pruritogens, but normal responses to a variety of painful
stimuli.8 Three lines of evidence suggested that GRP sig-
nalling at the spinal level was required for itch: (a) intra-
thecal administration of GRP receptor (GRPR) agonists
evoked scratching, while antagonists reduced scratching
in response to injected pruritogens; (b) in situ hybridisa-
tion revealed that the GRPR was expressed by neurons
in lamina I of the dorsal horn; (c) a subsequent study
from the same group showed that ablation of spinal
GRPR-expressing neurons with saporin conjugated to
bombesin (an amphibian homologue of GRP) resulted
in reduced responsiveness to a variety of pruritogens.9
This study also demonstrated that itch behaviours
following administration of histamine-independent
pruritogens such as chloroquine were substantially
reduced in GRPR knockout mice, whereas histamine-
dependent responses were much less aﬀected.9 Further
evidence for a role of spinal GRP signalling in hista-
mine-independent itch came from the ﬁnding that a
GRPR antagonist delivered directly to the spinal cord
signiﬁcantly reduced the responses of superﬁcial dorsal
horn neurons to intradermal chloroquine but not to
intradermal histamine.10
There has been considerable debate concerning the
source of GRP in the spinal cord. A number of studies
have provided evidence that GRP is expressed by a spe-
ciﬁc subset of peptidergic primary aﬀerents,8,11–13 and it
has been suggested that the GRP released by these aﬀer-
ents acts through spinal GRPR to mediate itch.8
However, several other groups have failed to detect
GRP mRNA in primary aﬀerents, using a variety of
methods, including in situ hybridisation, RT and real-
time polymerase chain reaction, and RNA seq.14–18 In
addition, it has been reported that the antibodies that
had been used to reveal GRP in the dorsal root gan-
glion8,13 can cross react with substance P,14,19 which is
expressed by many peptidergic primary aﬀerents.20,21
mRNA for GRP has been identiﬁed in the dorsal
horn14–16,18,22,23 and the GRP-expressing cells can be
identiﬁed in a mouse line (Tg-GRP-EGFP) in which
enhanced green ﬂuorescent protein (EGFP) is expressed
under control of the GRP promoter.14,19,24 It has
recently been shown that these cells represent a speciﬁc
population of excitatory interneurons in lamina II.19,25
Taken together with the evidence against primary aﬀer-
ent expression of GRP, these ﬁndings have led to
the alternative suggestion that GRP released by itch-
activated spinal interneurons plays an important role in
histamine-independent itch.14,24,26 To test this hypoth-
esis, we have looked for evidence that chloroquine can
activate GRP-expressing dorsal horn interneurons.
As GRP cannot be detected in the cell bodies of these
neurons with immunocytochemistry,19 we used the
Tg(GRP-EGFP) line. EGFPþ cells in this mouse are
mainly present in lamina II,19 and it has been shown
that >90% of these possess GRP mRNA.14To reveal
activated neurons, we stained for the transcription
factor Fos,27 which has been used in several previous
studies,28–32 and for phosphorylated extracellular
signal-regulated kinases (pERK).33,34
Methods
All animal experiments were approved by the Ethical
Review Process Applications Panel of the University of
Glasgow and were performed in accordance with the
European Community directive 86/609/EC and the UK
Animals (Scientiﬁc Procedures) Act 1986.
Fos induction
Six adult Tg(GRP-EGFP) mice of either sex (16–25 g;
Gene Expression Nervous System Atlas [GENSAT])
were used to investigate Fos expression after intradermal
injection of chloroquine or vehicle. The skin on the lat-
eral aspect of the hindlimb was shaved on the day before
stimulation, and in order to prevent scratching or biting
of the injected area during the postinjection survival time
(which would result in nociception-activated Fos), an
Elizabethan collar (Harvard Apparatus, #72-0056) was
applied at the time of shaving. Animals were brieﬂy
anaesthetised with isoﬂurane, and injections of either
chloroquine (40 mg dissolved in 10 ml of phospate-buf-
fered saline [PBS], n¼ 3 mice) or vehicle (10ml PBS,
n¼ 3 mice) were made into the lateral aspect of the left
calf, after which the mice were allowed to recover from
anaesthesia. The success of the intradermal injection was
assessed by the formation of a small bleb6,7 in the calf
skin. They were reanaesthetised with pentobarbitone
(20mg i.p.) and perfused through the left ventricle with
ﬁxative that contained 4% freshly depolymerised formal-
dehyde 2 h after the stimulus.
The L3 spinal segment (which contains the great
majority of cells activated by these stimuli) was removed
and postﬁxed for 2 h in the same ﬁxative. The contralat-
eral (right) side was notched to allow identiﬁcation, and
the tissue was cut into 60 mm thick transverse sections
with a vibrating blade microtome (Leica VT1200).
These were immersed in 50% ethanol for 30min to
enhance antibody penetration and then multiple-labelling
immunoﬂuorescence staining was performed as described
previously.19,35 The sections were incubated for three
days in the following combination of primary anti-
bodies: mouse monoclonal antibody NeuN (Millipore;
MAB377; diluted 1:500), chicken anti-EGFP (Abcam,
ab13970; diluted 1:1000), and rabbit anti-Fos (Santa
Cruz Biotechnology, sc-52; diluted 1:5,000). They were
then incubated overnight in species-speciﬁc secondary
antibodies that were raised in donkey and conjugated to
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Alexa 647, Alexa 488, or Rhodamine Red (Jackson
Immunoresearch, West Grove, PA, USA). Secondary
antibodies were diluted 1:500 (Alexa 647 and Alexa 488)
or 1:100 (Rhodamine Red). All antibodies were diluted in
PBS that contained 0.3% Triton X-100 and incubations
were at 4C. Following the immunocytochemical reaction,
sections were stained with 40,6-diamidino-2-phenylindole
(DAPI) to reveal nuclei, mounted in antifade medium and
stored at 20C.
Sections were scanned with a Zeiss LSM 710 confocal
microscope equipped with Argon multiline, 405 nm
diode, 561 nm solid state, and 633 nm HeNe lasers.
They were initially viewed with epiﬂuorescence optics,
and three sections from the chloroquine-injected mice
that contained numerous Fosþ cells were selected from
each animal, before EGFP was observed. Z-series (2mm
spacing) were then scanned through the full thickness of
each section with the 40 oil-immersion lens (numerical
aperture 1.3), with the confocal aperture set to 1 Airy
unit. These scans included the central part of the dorsal
horn, which contained the activated cells. The z-stacks
from chloroquine-injected mice were analysed with
Neurolucida for Confocal (MBF Bioscience, Williston,
VT, USA). The outline of the grey matter was drawn,
and the ventral border of the GRP plexus (which corres-
ponds approximately to the boundary between the inner
and outer parts of lamina II19) was determined from a
maximum intensity projection and plotted onto the
drawing. The mediolateral extent of the region that con-
tained a high density of Fosþ cells was delineated by
drawing two parallel lines that were orthogonal to the
laminar boundaries (see Figure 1).
Initially, only the channels corresponding to NeuN
and DAPI were viewed, and the locations of all neurons
(NeuNþ cells) that lay within this region were plotted
onto the drawing. To avoid overcounting cells that were
split during sectioning,36 we included cells if at least
part of the nucleus (stained with DAPI) was present
in the ﬁrst optical section of the z-series and excluded
them if part of the nucleus was present in the last optical
section.37 The channel corresponding to Fos was then
viewed, and the presence or absence of staining in each
of the neurons in the sample was recorded. Finally, the
EGFP channel was viewed and all neurons that were
EGFPþ were identiﬁed on the drawing. As Fosþ cells
were present at highest density in lamina I and the outer
part of lamina II (lamina IIo), we determined the pro-
portion of all neurons that were located within this
region and between the two parallel lines that were
Fos-immunoreactive. We then determined the propor-
tion of GFPþ neurons within this volume that were
Fos-immunoreactive. Sections from the PBS-injected
mice were also examined with the confocal micro-
scope to test for the presence of Fos-immunoreactive
neurons.
Phosphorylation of ERK
In initial studies, we performed intradermal injections of
chloroquine or PBS and allowed a 5-min survival time
before perfusion ﬁxation, as phosphorylation of ERK
occurs rapidly following stimulation.33–35,38 However,
although we observed numerous pERK-positive cells in
the superﬁcial dorsal horn of the ipsilateral L3 segment
in the chloroquine-injected mice, there were also many
pERKþ cells in the corresponding region in PBS-injected
mice. This is likely to have been caused by the mechan-
ical noxious stimulus that results from needle insertion
and distension of the skin during the intradermal injec-
tion.6 In subsequent experiments, we therefore allowed a
longer postoperative survival time (30min). Six adult
Tg(GRP-EGFP) mice of either sex (16–23 g; GENSAT)
were anaesthetised with isoﬂurane and received intrader-
mal injections of chloroquine (40mg in 10ml, n¼ 3 mice)
or PBS (10ml, n¼ 3 mice) into the left calf, which had
been shaved the day before, as described earlier. The
mice were maintained under isoﬂurane anaesthesia
throughout the survival period. They then received pento-
barbitone (20mg i.p.) prior to perfusion ﬁxation
(a described earlier), which was carried out 30min after
the intradermal injection. The tissue was processed exactly
as described for the Fos experiments, except that the
Fos antibody was replaced with rabbit anti-pERK (Cell
Signaling Technology, 9101; diluted 1:500). Confocal
scanning and analysis were performed as described for
the Fos experiments.
Characterisation of antibodies
The EGFP antibody was raised against recombinant full--
length EGFP, and the distribution of staining matches
that of native EGFP. The mouse monoclonal antibody
NeuN was raised against cell nuclei extracted from
mouse brain39 and apparently labels all neurons but no
glial cells in the rat spinal dorsal horn.40 The Fos antibody
was raised against a peptide corresponding to the N-ter-
minus of human Fos. The pERK antibody detects p44
and p42 MAP kinase (Erk1 and Erk2) when these are
phosphorylated either individually or dually at Thr202
and Tyr204 of Erk1 or Thr185 and Tyr187 of Erk2. It
does not cross-react with the corresponding phosphory-
lated residues of JNK/SAPK or of p38 MAP kinase or
with nonphosphorylated Erk1/2 (manufacturer’s speciﬁ-
cation). Speciﬁcity of both Fos and pERK antibodies
was demonstrated by the lack of staining in nonstimulated
areas (e.g. the contralateral dorsal horn).
Statistics
Data were formatted into 2 2 contingency tables for each
animal, with rows corresponding to presence or absence of
EGFP and columns to presence or absence of Fos or
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pERK. To determine whether there was a consistent dif-
ference in the proportions across the tables for the diﬀerent
cell types, we used the Mantel–Haenszel analysis.41
Breslow–Day testing for homogeneity of the odds ratio
was conducted prior to computation of the Mantel–
Haenszel odds ratio and 95% conﬁdence intervals.
Results
Fos
Injection of chloroquine into the calf, followed by a sur-
vival time of 2 h, resulted in expression of Fos in neurons
in the superﬁcial part of the dorsal horn of the L3
segment ipsilateral to the injection site. The cells were
found throughout the length of the segment but were
restricted to a narrow mediolateral band (around
100 mm wide) in the middle part of the dorsal horn
(Figure 1a), which corresponds to the central projection
zone of primary aﬀerents from the lateral part of the
calf.42 They were largely restricted to laminae I and IIo
and were rarely seen in deeper parts of the dorsal horn.
Within the delineated region, the mean total number of
neurons in laminae I–IIo pooled from three sections
from each animal varied from 386–440 (n¼ 3 mice),
and the proportion of these that showed Fos was 18%
(Table 1). In the PBS-injected mice, only very occasional
cells showing Fos were evident (Figure 1b).
Figure 1 Fos in the dorsal horn following intradermal injection of chloroquine.
(a) A transverse section through the dorsal horn from the L3 segment of a GRP-EGFP mouse, ipsilateral to the side in which chloroquine
(CQ) had been injected intradermally 2 h prior to perfusion fixation. Fos immunoreactivity (magenta) is superimposed on a dark-field (DF)
image. There is a cluster of Fosþ cells in the superficial part of the dorsal horn, and these are concentrated between the two dashed lines.
(b) An equivalent section from a mouse that had received an intradermal injection of PBS, in which no Fosþ cells are visible. (c–e) Higher
magnification views from the section shown in a to show the relationship between EGFP (green) and Fos. Note that although the cells are
intermingled, there are none that are double labelled in this section. All sections are maximum intensity projections of confocal z-series
(2mm z-separation) through the full thickness of the 60 mm section. Scale bars: a, b¼ 100 mm; c–e¼ 50mm.















Fos 417.7 (386–440) 74 (67–78) 55 (42–62) 4.0 (1–7) 17.7 (17.4–18.3) 6.8 (2.4–11.3)
pERK 398 (309–475) 82.7 (59–110) 50 (45–60) 1.3 (1–2) 20.9 (16.6–26.8) 2.8 (1.7–4.4)
Note. pERK: phospho extracellular signal-regulated kinase; GRP: gastrin-releasing peptide; EGFP: enhanced green fluorescent protein. The table shows
quantitative data from the region delineated by high levels of Fos or pERK, and were obtained from three mice in each case.
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As reported previously,14,19,24,25 GRP-EGFP neurons
were particularly numerous in lamina II, but were occa-
sionally seen in lamina I, and were also scattered through
the deeper parts of the dorsal horn (Figures 1c,e and 2).
Although there was considerable overlap in the distribu-
tion of GRP-EGFP and Fos, relatively few of the GRP-
EGFP cells were Fos-immunoreactive (Figure 1). The
mean number of GRP-EGFP cells that were sampled
in lamina I-IIo in the delineated area was 55, and of
these, 7% were Fos-immunoreactive (Table 1).
To determine whether the presence of Fos among
GRP-EGFP cells was signiﬁcantly less frequent than
that in the general population of neurons, we measured
the common odds ratio for the three mice (Table 2). The
95% conﬁdence interval was below 1, indicating that the
GRP-EGFP cells were signiﬁcantly less likely than other
neurons in this region to express Fos.
pERK
Thirty minutes after chloroquine injection, numerous
pERK-positive cells were seen in the ipsilateral L3 seg-
ment, while in contrast, very few pERK cells were seen in
the mice that had received injection of PBS (Figure 2).
The distribution of pERK cells in the chloroquine-
injected mice was similar to that of Fos-positive neurons
Figure 2 pERK in the dorsal horn following intradermal injection of chloroquine.
(a) A transverse section through the dorsal horn from the L3 segment of a GRP-EGFP mouse, ipsilateral to the side in which chloroquine
(CQ) had been injected intradermally 30min prior to perfusion fixation. pERK immunoreactivity (magenta) is superimposed on a dark-field
(DF) image. There is a cluster of pERKþ cells in the superficial dorsal horn, which is concentrated between the two dashed lines. (b) An
equivalent section from a mouse that had received an intradermal injection of PBS, in which no pERKþ cells are visible in the superficial
laminae. (c–e) Higher magnification views from the section illustrated in a show the relationship between EGFP (green) and pERK. Note
that although the cells are intermingled, there are none that are double labelled in this section. All sections are maximum intensity
projections of confocal z-series (2mm z-separation) through the full thickness of the 60 mm section. Scale bars: a, b¼ 100 mm; c–e¼ 50mm.










Fos 0.259 13.92 1 <0.001 0.32 0.17–0.59
pERK 0.937 32.56 1 <0.001 0.09 0.03–0.25
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described earlier, forming a narrow mediolateral band in
the middle part of the dorsal horn throughout the L3
segment. The total number of neurons in laminae I-IIo
within the region delineated by pERK-immunoreactivity
varied from 309 to 475 (n¼ 3 mice), and the proportion
of these that were pERK-immunoreactive was 21%
(Table 1). Again, although numerous GRPþ cells were
present in this region (mean 50 cells), relatively few of
these (3%) were pERK-immunoreactive (Figure 2c–e).
The 95% conﬁdence interval for the common odds ratio
was below 1, indicating that GRP-EGFP cells were sig-
niﬁcantly less likely than other neurons to have phos-
phorylated ERK (Table 2).
Discussion
The main ﬁndings of this study are that following
intradermal injection of 40 mg chloroquine into the calf,
around 20% of neurons in laminae I-IIo in the
somatotopically appropriate region of L3 upregulate
Fos and phosphorylate ERK. However, although the
activated cells showed an overlapping distribution with
GRP-EGFP neurons, the latter were seldom Fos- or
pERK-positive.
Fos and pERK as markers for itch activation
Several previous studies have used expression of Fos to
identify neurons in the spinal dorsal horn that were acti-
vated by various pruritogens, including chloroquine, or
in models of chronic itch.30,32,34,43–50 Between them,
these studies have involved intradermal injections into
several body regions: the cheek, neck, back, calf, and
hindpaw. In each case, Fosþ neurons have been identi-
ﬁed in laminae I–II of the corresponding spinal cord seg-
ments or spinal trigeminal nucleus. The distribution of
Fosþ cells seen in the present study was therefore entirely
consistent with these reports. As very few Fos cells were
seen following an equivalent injection of the vehicle
(PBS), it is highly likely that the Fos was induced as a
result of the chloroquine and therefore represents the
response to a pruritic stimulus.
There have apparently been very few reports of ERK
phosphorylation in itch models. Zhang et al.34 showed
that histamine injected intradermally in the neck or hind-
paw caused phosphorylation of ERK, which could be
detected in the superﬁcial dorsal horn, peaking 30min
after the stimulus. However, they found that intradermal
injections of chloroquine that were suﬃcient to induce
scratching did not evoke pERK. It is diﬃcult to explain
the discrepancy between their ﬁndings and those
reported here, although in their study, the mice were
not anaesthetised, and it is therefore possible that
scratching of the aﬀected area or activity in descending
systems that are inactive during general anaesthesia
suppressed ERK phosphorylation. It is unlikely that dif-
ferences in the site of injection (neck in Zhang et al. and
calf in the present study) were responsible for the diﬀer-
ent results, as Fos studies have shown very similar pat-
terns of expression when pruritogens were injected into
diﬀerent sites. We found very little pERK in animals that
had survived 30min after PBS injection, which suggests
that the phosphorylation was evoked by the chloroquine
and therefore represents a pruritic response. However,
our preliminary experiments with 5-min survival times
indicated that the injection itself could cause signiﬁcant
phosphorylation of ERK. This was clearly very short
lived, as it had completely subsided by 30min.
Comparing our ﬁndings with Fos and pERK shows
that there was a very similar distribution of labelled cells
and that a comparable proportion of lamina I-IIo neu-
rons within the somatotopically appropriate region was
aﬀected (20% in each case). Since ERK phosphoryl-
ation is an upstream regulator of Fos in the dorsal
horn,51 it is likely that the two markers were labelling
equivalent populations of neurons, and the ﬁnding that
GRP-EGFP cells were underrepresented with both mar-
kers is consistent with this suggestion.
Interestingly, Zhang et al.34 reported that blocking
phosphorylation of ERK with a MEK inhibitor reduced
scratching behaviour in response to histamine but not
to chloroquine. Our ﬁndings indicate that ERK is phos-
phorylated following intradermal injection of chloro-
quine but presumably it is not required for the resulting
behaviour.
The identity of the itch-activated neurons in laminae
I-IIo is not yet known, although it is likely that the great
majority are interneurons,28 and it will therefore be
important for future studies to determine which neuro-
chemical classes of interneuron show Fos or pERK fol-
lowing pruritogen injections. We have recently provided
evidence that four nonoverlapping populations, deﬁned
by expression of GRP, neurotensin, neurokinin B, and
substance P, can be identiﬁed among the excitatory inter-
neurons in laminae I–III.19,25 However, the neurotensin
and neurokinin B populations are both concentrated in
the inner part of lamina II and lamina III and are there-
fore unlikely to be involved in itch. At present, the sub-
stance P-expressing cells are diﬃcult to identify with
immunocytochemistry due to the low level of peptide
present in their cell bodies.
A role for GRP-expressing interneurons
in chloroquine-evoked itch?
There is considerable evidence that the GRPR plays an
important role in several forms of itch,1 including that
evoked by chloroquine.8,10 As it has been suggested that
GRP-expressing dorsal horn interneurons are part of
the itch pathway,14,24,26 we were surprised to ﬁnd that
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GRP-EGFP cells were underrepresented among those
that showed either Fos or pERK. It is likely that the
dose of chloroquine we used was suﬃcient to cause itch-
ing, as similar doses have evoked scratching or biting in
other studies in the mouse.52,53 In addition, we have
found that intradermal injection of 40 mg of chloroquine
into the calf in mice without Elizabethan collars leads
to biting of the injected area (EP unpublished data),
and this dose was suﬃcient to evoke Fos or pERK in
a substantial proportion (20%) of the neurons in lami-
nae I–IIo in this study.
This leaves several possible explanations for this para-
dox. (1) A signiﬁcant number of GRP-EGFP cells may
have been activated without expressing Fos or phosphor-
ylating ERK, and the risk of false-negative results should
always be considered with studies involving these activ-
ity-dependent markers. It is also possible that a relatively
low level of activation is required to induce release of
neuropeptides, including GRP. (2) It may be that suﬃ-
cient GRP is released from the relatively few GRP-EGFP
cells that were activated. (3) Solorzano et al.14 reported
that only 70% of neurons with GRP mRNA were
EGFPþ in this mouse line and therefore EGFP-negative
GRP-expressing neurons may have been activated.
However, this explanation would require that there was
a speciﬁc subpopulation of GRP-expressing neurons that
lacked EGFP and that these were selectively activated by
chloroquine.
Alternatively, the GRP-expressing dorsal horn inter-
neurons may not be critically involved in itch pathways.
There continues to be considerable debate about whether
GRP is released from primary aﬀerents,12,24 and if it is
then this would be consistent with our ﬁndings.
However, the majority view now appears to be against
primary aﬀerents as a source of GRP,15–18 at least in
naı¨ve animals.14
Finally, it is possible that the GRPR on lamina I
neurons is activated by a diﬀerent peptide. Although
the other main bombesin-like peptide, neuromedin B,
is expressed in primary aﬀerents,15–18 it has a very
low aﬃnity for the GRPR54 and is therefore unlikely
to mediate its activation following pruritic stimula-
tion. However, there may be another, as yet
unknown, peptide that forms the link between prur-
iceptive primary aﬀerents and the GRPRs that are
expressed by lamina I neurons, and the fact that
there is an orphan receptor (BB3) would be consis-
tent with this suggestion.54
Conclusions
The results of this study show that both Fos and
pERK can be used to identify cells that have been acti-
vated by intradermal injections of the pruritogen
chloroquine and that similar numbers of cells are
labelled for each marker. However, they do not support
the suggestion that GRP-expressing interneurons in the
superﬁcial dorsal horn are preferentially activated by
chloroquine.
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